The entire 36-week data for the remaining subjects in the trial is anticipated in the second quarter of this year.

Sep. 9, 2024 — Scientists developed a highly promising gene therapy to treat glaucoma -- a debilitating eye condition that can lead to complete vision loss, and which affects around 80 million ...

Treatment shows potential to slow the progression of human degenerative eye diseases, including retinitis pigmentosa.

Medera is a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing a range of next-generation therapeutics. Medera operates via ...

Certified brain injury specialist Melissa Volkert has been working as an occupational therapist since 2007 and has a ...

Neurotech Pharmaceuticals’ gene therapy comes in a surgical implant, and it’s now the first FDA-approved treatment for a rare vision-loss disorder. The approval handed out on March 5 covers ...

"I'll never forget [that moment]," Kharufeh said. "And it sounds so little. It's just like, 'Okay, a little blue comforter.' But in that moment that was everything to me, and I literally cried for ...

It is vital for clear vision, as it provides up to 75% of the total focusing ... This clinical trial revolved around an experimental stem cell therapy called cultivated autologous limbal epithelial ...

Share on Pinterest An experimental stem cell therapy could help reverse corneal damage in people with a vision-threatening eye condition. Image credit: daliloveart/Getty Images. Researchers ...

An additional analysis of CALEC's impact on vision showed varying levels of improvement ... The CALEC trial is the first human study of a stem cell therapy to be funded by the National Eye ...

the therapy—a transplant of stem cells from the person’s other healthy eye—appeared to safely restore the surface of people’s severely damaged corneas, often improving their vision as well.